ERAS — Erasca, Inc.

Is ERAS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Erasca, Inc. (ERAS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $18.07. The rating moved from Neutral to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

Erasca, Inc. (ERAS) is a clinical-stage oncology developer whose near-term outlook is primarily driven by upcoming clinical milestones and the availability of capital to fund programs. The company benefits from a focused pipeline and a market environment where successful clinical data can attract partnership or M&A interest, but it faces typical small-cap biotech risks including binary trial outcomes and potential dilution. In the current quiet macro window, the stock is likely to trade on company-specific news flow; upside scenarios depend on positive readouts or strategic collaborations, while downside is tied to adverse trial or funding developments.

Key factors

  • Clinical-stage oncology pipeline with near- to medium-term catalysts (trial readouts and dose-escalation updates) that can drive binary moves in share price
  • Strategic focus on targeted therapies that address solid-tumor indications where clear biomarker-driven approaches may improve success probabilities
  • Biotech/Pharma M&A environment remains constructive for companies with validated clinical data, which can create strategic exit opportunities or partnership interest
  • Market-wide steady risk appetite in the short window limits large directional moves absent company-specific news
  • Potential for partnership, collaboration, or CDMO demand tailwinds from sector-level biologics and diagnostic themes that can indirectly benefit company prospects
  • Valuation and expectation levels imply the market is pricing in clinical execution risk; relative valuation sensitivity to trial outcomes is high

Risks

  • Clinical trial failure, negative safety signals, or missed endpoints that would materially reduce clinical value
  • Limited cash runway and ongoing high cash burn typical of clinical-stage biotech, creating dilution risk if additional financing is needed
  • Regulatory risk and uncertainty around approval pathways and labeling for oncology assets
  • Competition from larger pharma and other targeted-therapy developers with deeper resources and broader pipelines
  • Commercialization and payer/reimbursement uncertainty if an asset reaches approval
  • Market volatility and sector rotation away from growth/biotech could compress multiples even for positive clinical outcomes

See today's live rating, score and targets

Members see the live hourly rating for ERAS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.